UNSPSC 51282946: Temafloxacin hydrochloride

This classification denotes a quinolone antibiotic with the molecular formula C21H18F3N3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OC5IGJ7J6I, chemically known as 3-quinolinecarboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride, (+-)- but generally known as temafloxacin hydrochloride, which bears US NIH Compound Identifier 60020.

UNSPSC 51282946 Temafloxacin hydrochloride is a Commodity code that represents a narrow pharmaceutical product line—a specific fluoroquinolone antibiotic—but recent state and local procurement activity under this code shows little material alignment with the product itself. The code designation appears to be a technical catalog reference rather than an active procurement category; recent opportunities tagged to this code instead reflect broader pharmaceutical sourcing, medical supply distribution, and pharmacy benefit program management. State and local governments are acquiring generic pharmaceuticals, over-the-counter products, naloxone, and medical emergency supplies through cooperative purchasing alliances, county health departments, and municipal fire departments, not sourcing temafloxacin hydrochloride as a discrete line item.

Activity is concentrated in health and human services procurement—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs (April 3, 2026 response date), Seminole County, Florida's IFB for naloxone and drug deactivation systems (July 26, 2023 deadline), and the City of Tampa's IFB for medical and first aid supplies for its Fire Department Rescue Division (March 13, 2026 deadline, estimated contract value $700,000.00). MMCAP participants include multiple state and local jurisdictions with wholesaler distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The Tampa procurement is designated as a sheltered Small Local Business Enterprise (SLBE) opportunity with a 5 percent bid discount not to exceed $10,000. Recent opportunities span Florida, Texas, and Minnesota; the code shows no meaningful geographic concentration and limited recent substantive activity specific to temafloxacin hydrochloride itself.